Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Nixon

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 14, 2009
Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trialsRichard Grieve, Richard Nixon, Simon G Thompson
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?David Tyas, John Kerrigan, Nicola Russell, et al.
Health Economics|February 3, 2005
Parametric modelling of cost data: some simulation evidenceAndrew Briggs, Richard Nixon, Simon Dixon, et al.
Psychopharmacology Bulletin|February 12, 2025
Raised Creatine Kinase with Numerous Antipsychotics Responded to ClozapineMichael Dixon, Richard Nixon, James O'Neill, et al.
Current Medical Research and Opinion|September 30, 2014
Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27Richard Nixon, Gorana Capkun-Niggli, Niklas Bergvall, et al.
Biometrical Journal. Biometrische Zeitschrift|January 30, 2015
A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessmentEd Waddingham, Shahrul Mt-Isa, Richard Nixon, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 26, 2011
Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisalManuel Gomes, Richard Grieve, Richard Nixon, et al.
Health Economics|December 28, 2006
Multilevel models for estimating incremental net benefits in multinational studiesRichard Grieve, Richard Nixon, Simon G Thompson, et al.
Health Economics|September 24, 2004
Using multilevel models for assessing the variability of multinational resource use and cost dataRichard Grieve, Richard Nixon, Simon G Thompson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2007
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UKMichelle Orme, John Kerrigan, David Tyas, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 14, 2009
Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trialsRichard Grieve, Richard Nixon, Simon G Thompson
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?David Tyas, John Kerrigan, Nicola Russell, et al.
Health Economics|February 3, 2005
Parametric modelling of cost data: some simulation evidenceAndrew Briggs, Richard Nixon, Simon Dixon, et al.
Psychopharmacology Bulletin|February 12, 2025
Raised Creatine Kinase with Numerous Antipsychotics Responded to ClozapineMichael Dixon, Richard Nixon, James O'Neill, et al.
Current Medical Research and Opinion|September 30, 2014
Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27Richard Nixon, Gorana Capkun-Niggli, Niklas Bergvall, et al.
Biometrical Journal. Biometrische Zeitschrift|January 30, 2015
A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessmentEd Waddingham, Shahrul Mt-Isa, Richard Nixon, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 26, 2011
Statistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisalManuel Gomes, Richard Grieve, Richard Nixon, et al.
Health Economics|December 28, 2006
Multilevel models for estimating incremental net benefits in multinational studiesRichard Grieve, Richard Nixon, Simon G Thompson, et al.
Health Economics|September 24, 2004
Using multilevel models for assessing the variability of multinational resource use and cost dataRichard Grieve, Richard Nixon, Simon G Thompson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2007
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UKMichelle Orme, John Kerrigan, David Tyas, et al.
Pageof 2